rs10751659 — PRG3 PRG3 Eosinophil Major Basic Protein Homologue Variant

Intronic variant in the PRG3 gene encoding eosinophil major basic protein homologue (MBPH/MBP-2) at chromosome 11q12.1; the rarer C allele tags variation in PRG3 expression and is associated with altered eosinophil granule protein activity implicated in allergic inflammation, IgE-mediated tissue damage, and atopic disease susceptibility

See your personal result for PRG3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PRG3 — The Eosinophil's Second Weapon in Allergic Tissue Damage

Buried inside the granules of every activated eosinophil lies a pair of cationic proteins — twin weapons in the allergic immune arsenal. The better-known of the two is eosinophil major basic protein (MBP, encoded by PRG2), a highly positively charged protein that disrupts cell membranes, triggers mast cell degranulation, and drives airway remodeling in asthma and atopic disease. Less appreciated is its structural cousin: eosinophil major basic protein homologue, MBPH11 MBPH
Also known as MBP-2, encoded by the PRG3 gene (proteoglycan 3) on chromosome 11q12.1, immediately adjacent to PRG2. PRG3 was identified in 1999 as a distinct eosinophil granule protein with 63% amino acid identity to PRG2-encoded MBP. rs10751659 is an intronic variant in the PRG3 gene that tags variation in PRG3 expression and eosinophil granule protein activity.

The Mechanism

PRG3 encodes MBPH, a C-type lectin-like protein stored in the secondary (specific) granules of eosinophils — the same compartment as EPX (eosinophil peroxidase), ECP (eosinophil cationic protein), and EDN (eosinophil-derived neurotoxin). When eosinophils are activated by IgE-mediated signals, IL-5, or allergen stimulation, they degranulate, releasing MBPH along with its companion proteins into the surrounding tissue. MBPH carries a net cationic charge of +8 at neutral pH22 MBPH carries a net cationic charge of +8 at neutral pH
Compared to +16 for MBP1; the reduced charge of MBPH explains why it shows similar but less potent cytotoxic and stimulatory activities compared to MBP1 in vitro. Despite this charge difference, MBPH retains the capacity to kill parasites and tumor cells, stimulate basophil and neutrophil activation, and directly damage epithelial cells.

rs10751659 is located within an intron of PRG3 and does not alter the protein coding sequence directly. Intronic variants in eosinophil granule protein genes typically act as expression quantitative trait loci (eQTLs), influencing how much of the granule protein each eosinophil produces — directly setting the quantity of MBPH available for release upon activation. The C allele at this position (the minor allele, ~14.5% globally) marks variation in this expression regulation. The PRG3 and PRG2 genes share conserved GATA and STAT transcription factor binding sites in their promoters33 conserved GATA and STAT transcription factor binding sites in their promoters
GATA-1 and STAT5 bind the proximal promoters of both PRG2 and PRG3, driving eosinophil-restricted transcription; IL-5 signals through STAT5, linking eosinophil maturation cytokine exposure to granule protein expression levels.

The Evidence

MBPH was characterized in 1999 when Plager and colleagues44 Plager and colleagues
Plager DA et al. J Biol Chem 1999 — isolated hMBPH from eosinophil granules, detected transcript exclusively in bone marrow; demonstrated cytotoxic and basophil/neutrophil- stimulating activities with reduced potency relative to MBP1 identified a second cationic protein co-localizing with MBP1 in eosinophil secondary granules. The protein's disulfide bond architecture55 disulfide bond architecture
Mass spectrometry mapping by Wagner et al. 2007 confirmed two disulfide bonds (Cys20-Cys115, Cys92-Cys107) conserved with MBP1 and C-type lectins, plus six free sulfhydryl cysteine residues; the structural conservation supports shared functional mechanisms is conserved with MBP1 and with C-type lectin-like proteins, indicating evolutionary optimization for the same biological role: direct cytotoxicity via cationic membrane disruption.

The eosinophil granule protein family — MBP1, MBPH, ECP, EDN, and EPX — constitutes the primary effector mechanism of eosinophil-mediated tissue damage in allergic disease. MBP knockout mice are protected from experimental colitis66 MBP knockout mice are protected from experimental colitis
From Front Immunol 2021 review; eosinophilic infiltration also predicts poor response to medical therapy in ulcerative colitis, and elevated granule protein levels correlate with disease severity in asthma and atopic dermatitis. MBPH's contribution to this effector pool is at the emerging evidence stage for this specific intronic variant; the protein-level biology is well-established but the population-level genetics of this particular rs10751659 intronic tag SNP have not been characterized in large GWAS studies.

The notable population stratification of rs10751659 — with the C allele at ~20-25% in Europeans but approaching zero in East Asian populations — mirrors patterns seen in other eosinophil-related variants, where European populations carry greater diversity in eosinophil granule protein gene regulation.

Practical Actions

For CT heterozygotes and CC homozygotes, the actionable implications center on monitoring eosinophil activation and reducing triggers that cause eosinophil degranulation and MBPH release. MBPH released from eosinophils in airways, gut, and skin triggers mast cell degranulation and amplifies the local allergic response — creating a feedforward loop from the initial allergen exposure. The dominant allergic effector pathway driven by MBPH is eosinophil activation by IL-5 and IgE-mediated signaling; actions that reduce IL-5-driven eosinophil recruitment and activation address the specific mechanism at this locus.

Interactions

The PRG3 gene sits directly adjacent to PRG2 on chromosome 11q12.1, and both genes share regulatory machinery. rs11229030, a PRG2/PRG3 intergenic tag SNP, is associated with Crohn's disease susceptibility via eosinophil MBP-mediated gut epithelial damage — carriers of risk alleles at both PRG2 and PRG3 variants may face compounded eosinophil granule protein activity. The related coding variant rs34108746 in PRG3 (p.Tyr146Asp) directly alters the MBPH protein and is associated with eosinophil count at genome-wide significance across multiple large blood cell GWAS datasets.

Genotype Interpretations

What each possible genotype means for this variant.

TT Common PRG3 Form Normal

Common homozygous genotype with population-typical PRG3 eosinophil granule protein expression

You carry two copies of the T allele at rs10751659 — the most common genotype globally, present in approximately 73% of people worldwide (higher in East Asian populations where the T allele approaches fixation). The T allele is the population-major allele at this PRG3 intronic variant. Your eosinophil major basic protein homologue (MBPH) expression from PRG3 at this locus follows the typical population pattern. No elevated eosinophil granule protein activity is associated with this genotype at this variant.

CT PRG3 Carrier Intermediate

One copy of the rarer C allele, associated with variation in PRG3 eosinophil granule protein expression

The CT genotype places you in the intermediate group for PRG3 variation at this locus. MBPH (eosinophil major basic protein homologue) is stored in eosinophil secondary granules alongside ECP, EDN, and EPX. When eosinophils encounter IL-5, allergen stimulation, or IgE-mediated signaling, they degranulate and release MBPH into the local tissue environment. MBPH's cationic character allows it to disrupt cell membranes, trigger mast cell degranulation, and stimulate basophil activation — amplifying the local allergic response. The practical implication of the CT genotype is awareness that variation at this PRG3 locus may contribute to eosinophil activation tendencies, warranting monitoring of eosinophil counts alongside any allergic or atopic symptoms.

CC PRG3 Homozygous C High Risk

Two copies of the rarer C allele — highest variation in PRG3 eosinophil major basic protein homologue expression at this locus

As a CC homozygote at rs10751659, you carry two copies of the rarer allele at this PRG3 intronic variant. PRG3 encodes eosinophil major basic protein homologue (MBPH/MBP-2), a cationic protein stored in the secondary granules of eosinophils alongside ECP, EDN, and EPX. MBPH was characterized as a second eosinophil granule protein with 63% amino acid identity to MBP1 (PRG2 product), sharing the C-type lectin-like structural domain and the capacity for cytotoxicity, mast cell degranulation, and basophil activation — though with reduced potency due to its lower cationic charge (+8 vs +16).

PRG3 and PRG2 are controlled by shared GATA and STAT transcription factor binding sites in their promoters, ensuring eosinophil-restricted expression of both granule proteins. IL-5 signaling drives eosinophil maturation and granule protein production through STAT5 activation at these promoter sites. Intronic variation in PRG3 may modulate the efficiency of this transcriptional program, altering how much MBPH is synthesized per eosinophil during maturation in the bone marrow — setting the per-cell granule protein load available for release upon allergenic stimulation in peripheral tissues.

The notable frequency difference between European (~5% CC) and East Asian (~0% CC) populations suggests that this allelic variation at PRG3 may have been subject to different population histories and potentially differential selection in the context of infectious disease or atopy across ancestral environments.